Targeted therapies in small-cell lung cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert opinion on therapeutic targets

• Publication date

  2007-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14728222.11.8.1033PMID 17665976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small cell lung cancer

  2010cited by this paper
• A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

  2007cited by this paper
• Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy

  2007cited by this paper
• Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

  2007cited by this paper
• Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

  2007cited by this paper
• Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial

  2007cited by this paper
• Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.

  2007cited by this paper
• Non-small cell lung cancer: Clinical practice guidelines in oncology

  2006cited by this paper
• Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

  2006cited by this paper
• Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

  2006cited by this paper
• Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy

  2006influential reference
• Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

  2006cited by this paper
• Proteasome inhibitors in lung cancer.

  2006cited by this paper
• A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

  2006cited by this paper
• Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

  2006cited by this paper
• Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

  2006cited by this paper
• Targeting Gastrin-Releasing Peptide Receptors on Small Cell Lung Cancer Cells with a Bispecific Molecule that Activates Polyclonal T Lymphocytes

  2006cited by this paper
• Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

  2006cited by this paper
• Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

  2006cited by this paper
• Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

  2006cited by this paper
• Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.

  2006cited by this paper
• Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro.

  2006cited by this paper
• Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

  2006cited by this paper
• Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

  2006cited by this paper
• Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network

  2005cited by this paper
• Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• CALGB 30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC)

  2005influential reference
• Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission

  2005cited by this paper
• Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis

  2005cited by this paper
• Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

  2005cited by this paper
• Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients.

  2005cited by this paper
• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: A phase II clinical trial

  2005cited by this paper
• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  2005influential reference
• Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base.

  2005cited by this paper
• Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined Immunodeficient Mice

  2005influential reference
• Population-based analysis of prognostic factors and survival in familial melanoma.

  2005cited by this paper
• Anticoagulant drugs increase natural killer cell activity in lung cancer.

  2005cited by this paper
• The Hedgehog signaling pathway as a target for anticancer drug discovery.

  2005cited by this paper
• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

  2005cited by this paper
• Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

  2005cited by this paper
• Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.

  2004cited by this paper
• Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3.

  2004influential reference
• Novel targeted agents in the treatment of lung cancer

  2004cited by this paper
• Thalidomide in cancer medicine.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer

  2004cited by this paper
• Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents.

  2004cited by this paper
• Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.

  2004cited by this paper
• Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)

  2004cited by this paper
• A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer.

  2004cited by this paper
• The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

  2004cited by this paper
• Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

  2004influential reference
• Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

  2003cited by this paper
• Recurrent small cell lung cancer: update.

  2003cited by this paper
• Phase II study of imatinib in patients with small cell lung cancer.

  2003cited by this paper
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cited by this paper
• Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

  2003cited by this paper
• Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

  2002cited by this paper
• Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America

  2002cited by this paper
• Small cell lung carcinoma (SCLC): the angiogenic phenomenon.

  2002cited by this paper
• Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer

  2002cited by this paper
• Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

  2002cited by this paper
• A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

  2002cited by this paper
• Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer

  2002cited by this paper
• Anticoagulants in thrombosis and cancer: the missing link

  2002cited by this paper
• Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

  2002cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.

  2001cited by this paper
• Development of matrix metalloproteinase inhibitors in cancer therapy.

  2001cited by this paper
• Ubiquitin proteasome pathway: implications and advances in cancer therapy.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Receptor tyrosine kinase signalling as a target for cancer intervention strategies.

  2001cited by this paper
• The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.

  2000cited by this paper
• Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues.

  2000influential reference
• Therapeutic advances in small cell lung cancer

  2000cited by this paper
• Pathology of small-cell lung cancer

  2000cited by this paper
• Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

  2000cited by this paper
• Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer

  2000cited by this paper
• Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.

  1999cited by this paper
• Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.

  1999cited by this paper
• Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.

  1997cited by this paper
• Interferon Maintenance Therapy for Small Cell Lung Cancer: Improvement in Long-Term Survival

  1997cited by this paper
• Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.

  1997cited by this paper
• Activation of the cell death program by inhibition of proteasome function.

  1997cited by this paper
• Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.

  1996cited by this paper
• Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial.

  1996cited by this paper
• Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL.

  1996cited by this paper
• Immunohistochemical detection of Bcl-2 protein in small cell carcinomas.

  1996cited by this paper
• Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.

  1995cited by this paper
• A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

  1995cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of bcl-2 Gene Expression

  1994cited by this paper
• High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.

  1992influential reference
• Natural interferon alfa as maintenance therapy for small cell lung cancer.

  1992cited by this paper
• Human small‐cell lung‐cancer cells are cytokine‐resistant but NK/LAK‐sensitive

  1991cited by this paper
• Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma.

  1991cited by this paper
• Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells.

  1991cited by this paper

• ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy.

  2025cites this paper
• Drug-Eluting Beads Bronchial Arterial Chemoembolization in Treating Relapsed/Refractory Small Cell Lung Cancer Patients: Results from a Pilot Study

  2021cites this paper
• The Thorax

  2020cites this paper
• Application of computed tomography-based radiomics signature analysis in the prediction of the response of small cell lung cancer patients to first-line chemotherapy

  2019cites this paper
• Full Issue PDF Volume 34, Issue 1

  2019cites this paper
• Population pharmacokinetics and individualized lobaplatin regimen for the treatment of Chinese small cell lung cancer in the elderly

  2019cites this paper
• ProGRP as early predictive marker of non–small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment

  2019cites this paper
• Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model

  2018cites this paper
• Friend leukemia virus integration 1 promotes tumorigenesis of small cell lung cancer cells by activating the miR-17-92 pathway

  2017cites this paper
• Molecular analysis of circulating cell-free DNA in lung cancer

  2017cites this paper
• Usefulness of carcinoembryonic antigen in the diagnosis of small cell lung cancer combined with adenocarcinoma.

  2017cites this paper
• 1p/19q codeletion and RET rearrangements in small-cell lung cancer

  2016cites this paper
• Organ‐specific efficacy of HSP90 inhibitor in multiple‐organ metastasis model of chemorefractory small cell lung cancer

  2016cites this paper
• Hypermethylation of ATP‐binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line

  2016cites this paper
• Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

  2016cites this paper
• A Case of EGFR Mutation-positive Combined Small-cell Lung Carcinoma in a Nonsmoker in Whom Palliative Treatment with Gefitinib Was Successful

  2016cites this paper
• Origins, genetic landscape, and emerging therapies of small cell lung cancer

  2015cites this paper
• Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

  2014cites this paper
• Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  2014cites this paper
• Experimental evaluation of gene silencing as potential therapeutic option in the treatment of multiresistant Non-small-cell lung cancer

  2014cites this paper
• Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype

  2014cites this paper
• Effects of vinorelbine on cisplatin resistance reversal in human lung cancer A549/DDP cells.

  2013cites this paper
• Spectrum of pulmonary neuroendocrine proliferations and neoplasms.

  2013influential citation
• Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model

  2010cites this paper
• Recent Pharmacological Advances: Focus on Small-cell Lung Cancer

  2010cites this paper
• Tumores neuroendocrinos de pulmón. Estrategias de tratamiento en carcinoma de células pequeñas con enfermedad extensa

  2010cites this paper
• Appropriateness.

  2007cites this paper